You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD8 T cell responses

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in

Recruiting
  • COVID-19
    • Baltimore, Maryland
    • +1 more
    Feb 2, 2023

    Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

    Not yet recruiting
    • Metastatic Colorectal Adenocarcinoma
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 12, 2023

    Pancreatic Ductal Adenocarcinoma, NSCLC, Colorectal Cancer Trial (AFNT-211)

    Not yet recruiting
    • Pancreatic Ductal Adenocarcinoma
    • +4 more
    • (no location specified)
    Oct 23, 2023

    COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

    Active, not recruiting
    • COL6A3 Positive
    • +3 more
    • Aldesleukin
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 22, 2022

    Monitoring T Cell Responses in Melanoma, Lung and Other Cancer

    Recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +9 more
    • Biospecimen Collection
    • Electronic Health Record Review
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Oct 4, 2023

    Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia Trial in

    Suspended
    • Juvenile Myelomonocytic Leukemia
    • +27 more
    • CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
    • +2 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    Alterations in CD8aß and CD8aa T Cell Levels in Rheumatoid

    Not yet recruiting
    • Rheumatoid Arthritis
    • flow cytometry
    • (no location specified)
    Apr 12, 2023

    Multiple Sclerosis, Progressive Multifocal Leukoencephalopathy Trial run by the National Institute of Neurological Disorders and

    Not yet recruiting
    • Multiple Sclerosis
    • Progressive Multifocal Leukoencephalopathy
    • 89 Zr-Df-crefmirlimab
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    May 13, 2023

    Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 10, 2023

    HNSCC, Melanoma, Gynecologic Cancer Trial in Portland (DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2)

    Recruiting
    • HNSCC
    • +5 more
    • DP CD8 TIL
    • +2 more
    • Portland, Oregon
      Providence Portland Medical Center
    Jun 5, 2023

    B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • +2 more
    • CD19/CD22-bispecific CAR-T cells
    • Beijing, Beijing, China
      Liang Wang
    Oct 7, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    Melanoma, Melanoma Stage III Trial in New York (diagnostic test, drug, procedure)

    Recruiting
    • Melanoma
    • Melanoma Stage III
    • PET Scan
    • +3 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center (All Protocol Activities)
    Jun 24, 2022

    T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

    Recruiting
    • T-cell Acute Lymphoblastic Leukemia
    • +3 more
    • Universal CD7-specific CAR gene-engineered T cells
    • Beijing, Beijing, China
    • +2 more
    Aug 17, 2023

    Peripheral T Cell Lymphoma Trial in China (CAR-T Therapy)

    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • CAR-T Therapy
    • Hefei, Anhui, China
    • +7 more
    Jul 31, 2023

    Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (biological, drug, procedure)

    Completed
    Has Results
    • Recurrent Plasma Cell Myeloma
    • Refractory Plasma Cell Myeloma
    • Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Aug 3, 2022

    Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

    Recruiting
    • Extranodal NK T Cell Lymphoma
    • NK-Cell Leukemia
    • Anti-CD56 CAR T
    • Xuzhou, Jiangsu, China
      The Affiliated Hospital of Xuzhou Medical University
    Jul 10, 2023

    NSCLC, Small Cell Lung Cancer, Pancreas Cancer Trial in Shanghai (Infusion of iNKT cells and CD8+T cells)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • +5 more
    • Infusion of iNKT cells and CD8+T cells
    • Shanghai, Shanghai, China
      Shanghai Public Health Clinical Center
    May 6, 2022

    CD8+ T-cell PET/CT Imaging in COVID-19 Patients

    Recruiting
    • Lymphopenia Due to COVID-19
    • +2 more
    • [89Zr]Df-IAB22M2C PET/CT scan
    • Nijmegen, Gelderland, Netherlands
      Radboud university medical center
    Jun 2, 2022

    Metastatic Malignant Tumor in the Liver, Metastatic Uveal Melanoma Trial in Houston (Aldesleukin, Autologous CD8+

    Active, not recruiting
    • Metastatic Malignant Neoplasm in the Liver
    • Metastatic Uveal Melanoma
    • Aldesleukin
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 20, 2023

    Glioblastoma Trial in Gainesville (Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

    Not yet recruiting
    • Glioblastoma
    • Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
    • Gainesville, Florida
      University of Florida Health
    Jul 29, 2022

    Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

    Recruiting
    • Hairy Cell Leukemia
    • Hairy Cell Leukemia Variant
    • CD22CART cell infusion
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 25, 2023

    Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)

    Not yet recruiting
    • Stage IIIB(N2) Non-small Cell Lung Cancer
    • +3 more
    • Pembrolizumab 200 mg IV infusion
    • Beijing, Beijing, China
      Peking University
    May 30, 2023

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023

    CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

    Recruiting
    • CD70-positive Advanced Urologic Neoplasms
    • Anti-CD70 CAR-T cells
    • Shanghai, Shanghai, China
      Changhai Hospital
    Aug 11, 2023